"Cancer drugs don't compete on price," said Dr. Aaron Kesselheim, a researcher at Harvard Medical School and author of several studies of drug pricing. "Drug companies have market exclusivity and we require payers to cover cancer drugs - Medicare has six protected classes, including cancer."

Read More: http://investorshangout.com/post/view?id=4460...z4dI7K5XhI


It is all about funding. Cellceutix should re-apply for grants. I'd love to see NIH come forward and cherry pick but I doubt that's how they work.